Biosimilar medicines: the intersection of access, affordability, and innovation

3 February 2025

Director of Biosimilar Policy & Science at Medicines for Europe, […]

Building A Sustainable Market: new Medicines for Europe President sets out priorities

20 January 2025

Newly appointed Medicines for Europe President Stephan Eder discusses the […]

STADA’s Stephan Eder sets Access, Manufacturing and Sustainability at heart of Medicines for Europe Presidency

13 January 2025

Industry Proposes Phased Rollout of ePI for Patient Safety and Environmental Sustainability

8 January 2025

Maximising the impact of Biosimilar Medicines requires strategic action in Europe

5 December 2024

Medicines for Europe Statement on Unitary SPC Legislative Process

19 November 2024

Joint Industry Statement on EU-Mercosur Negotiations

18 November 2024

Council adoption of Urban Waste Water Treatment Directive will generate a tsunami of essential and critical medicine shortages across Europe

5 November 2024

New report highlights market access barriers for EU-based generic and biosimilar companies in third countries

31 October 2024

Urban Wastewater Treatment Directive risks undoing Europe’s efforts to improve the availability, affordability and accessibility of medicines

17 October 2024